..

fi a u a n rt u :t 6u1ufl lil rt o.: air rin n o cr1 or r wi''rtr 6

rT orr filvfiu'l.lni

Lrurilr,:q?U o::ru nr:drid'u"lunruturj: y ryr rt'ty U vI. Fl. lq ddo.

n?\: tvlTl "1 : I:.:fi ldrtvi':efi r n.: nr n:rumriu u r d's' h ddo'

uau ufir.

o. qiuo::H -- ii'tl. rt. rr.1:*ri -- tui6ao::il4:5ul -- i{'u'

t. r,{:?ilttfl r'tmariuv, {rrri.:irru' ll. qE nrf,tqn, {trri':i'u't

Itt. {iot{0.:.

osrt,sf.stt

tsBN 978-974-04-8131-7

fu fi vrd'tattil:ilei uo::r nr:liri{u"lunu"lurj:v tvrntlvr u

fitr{nri.rfi o e'rulu lq,ooo taiil lr.Ft. lqddo

T'1F11 lqdo UlYl

fi rufiiiI:.:fi rudrrvi.rXrnrn.: n:nituriyr urd'u [aooo-tood/lo,ooo/(to)]

In:. o-ttt" td-ost'st'o-lo, o -lele o d- 6n db eq, o -lqlq od- eq dds'f'a a-"-q '.."-- :on fifilldffiflHil1 fiurnru bd6ou1{Ft:uyll'{u uugl:}Ji s s

http://www.cu Pri nt.chu la.ac.th

mfr 6a uurvr.:qi uo::il nr:dri{u'lunu"lurj: v rvr rtlu u afi l,'l.nt.rqddo riJuauil:Jfi:J:.r tfi il u6 ue r n rdliitfrdo " rrulvtt.teiuo::r nr:rir

ie-utunu rwi.ttr6" yl.nt. bddd uonaT nrjil lrj6uu{iovri':fr o rrfir ldrfilia

umfi nu nr:ie-u talnltvn:fi fi.:nr:o!nqlJttu?fi::ileiuo::ilnr:dri{uqrJn:cr]

ur,rnr:rmvtti nr:drie"'uilr':d'.'rcrlntroni irrdu :vlrniflur ilu:guv'liuqrirnnSda a d c X d' -- f a 4 4nr:ririq:uttondm-uqtquu Lilatu030{vl15n :n [[nuLnilnalnln a$no

ld'irmri.:douu':ilr.re?uo::iln1:lirie-u"lueru"lu:J:vrmnt'ivtu 1'l.F[. loddo

'aua' ''-^--uvl't'Jimurnfrartfnr:ltvluft1lJl? tJ tlu',]111.1]Jfl :J Fl 9l'lUal Uf, 11tJ n1:vl','l',lq

orYufl oX:iulinr:u fi ru tfl uaril rt:n"lurJ:v ru olvr ru

v ft d a uu r r r.: e 3 u o r : u n r :dr i {u"lu rr u"lu rJ : v tvr nln u a:iu l'1. Ft.eY

rs ddo Q oY,lulw{nrurlil u ttn vnrBld.: n qr+nr ulu rai u t6 ur riu rtfi o nrr Iq qv , a I a Yv - t'-.Y.

fl va?n [unr: [fr .:ru ttn : 0rtd.: Inu n ruvu:1il'1fi n1: ioa nfl 1Fl]-Jfi 1fl 0vl{\ u qu Y d, - Vnrurlilu ttnv d'.:nqr+ [rln:'r riu nr: ttil ner nnlBl Lfl u tflun1:i1o'{ nqut,Iu

uonaln ft uilfl ni.qtrff oo.lrJ:v roiS rfl u{ r{i urtrqnls rtil n ttfrr ti.:fr a'lfiU1nruifrruqi ufi::lJ n1:?i1id'u frr u lirunl: ttl n"frufiu udr ti.:'[dil nr:

a

or:re ufi 6 n n*.rer nfi o rot of lvrfio tttr Ftxl'lu'l N ou {vr :.: q ru1 ofi fi'.: rfl uu::rur 6 n r :r 1 1 fl 't lvt 1{ n 1 : ttun ri

t r.r : il a i u fi : : I n r r i {a"lu n u"lurj : v rvr o'lil u ? o lJ CI ! q il n ru v dr.: r uq

tjirtj:',ttturnr':eiuo::ilnr:d,id'u"lunu"lu:J:vtvrFr'lilu lil.FL lqddd-lsddoJ"Yaudfr.:rirrfrunr:il51r-l:,:fiua:Jurut[tu tounru nillu:l {?1'liltuuvl-- "-----i t i I I:o{ fi Eilux u nr: nlr urJ:v ri'uq iln1v! n ntiui{u n1: ttv!il flilfi 'l: (AFRI MS)gl{i.r'[ fr dr u air rfi u n r :t o vr u otitt o uu q r n a n r riui {s vr fi 1 :x o t n o 56 n tfi o n r :9l

"lJ

rr:Jnuri.rfro uutrr.:q?uo::il nr:id'u"lunrulu:J:v tvrfl'lil uer nnrBr-[u u rilu

n1u'ro-{nqu

t il : il e i u r :: ru n r :i'i'stu n u'lurj : v rvr Ff'tr u y i',:'i r mf.: fi o " ttur u r ueiuo::il nr:ririd'u'lunulurj:r rvr eilvr u fl .Ft. leddo" e v rfl uil:v1utliqia

e Aa a o as e d v dn51N n15r,rYl',rfi u']T1ra1:il145u61:N n1lvt1'ta u tu Fru [[1^tyt u ilun uv'tYl ugrn dr ni yr u 1rJ'r fl uo vrTni{ufi rir.:rui{uluilu:cfil nyiru vr",:drfi atfr

oavA s^lwv ' a.i A vn1TTl?a U tutJUl4U In:!n1:il nil o{o U'l\: oVl6[O [tn v [y{0 Fl1'1iln1?fiu'M'l{li

ir ur rtr onfnlr uvlvr ri

n* fu^JU'F(Ft''r fl Fr:'rar:f unvr fnf .,r fi 'l n1 fi ufi fi u?{d')

rJ:vorurru:uoirJo::ilnr:i{alunrulurirv [r FIlil u-A?UYl lfld fiU'l'lFltJ l'rl.f[. leddo

.

(World Medical Association Declaration of Helsinki) .. .. (volunteer) (participant)

(Forum for Ethical Review Committees in Thailand FERCIT) (Council for International Organizations of Medical Science CIOMS) (Ethical Conduct for Research Involving Humans) ..

.

.. .. ..

. .. .. .. (standard operating procedure )

. ..

(biomedical research)

.. ( ) ..

..

.

..

. biomedical science social science research The Belmont Report , , .. Belmont Conference Center Smithsonion .. The Belmont Report

(Respect for person) (Beneficence) (Justice)

. (Respect for Person) .. (respect for human dignity) (interest) .. (free and informed consent) .. (respect for vulnerable persons) /

.. (respect for privacy and confidentiality)

. (Beneficence, Non-Maleficence) .. (balancing risks and benefits) ( ) .. (minimizing harm)

.. (maximizing benefit)

. (Justice) (fairness) (equity)

. (Informed Consent Process)

.. (information sheet)

(informed consent) ()

()

() () () () () () () () () () () ()

() / /

() () () () () ()

()

..

() ()

()

()

()

. (Inducement)

(invite)

.. /

.. (phase I clinical trial) (phase III)

.. / / ..

. (Privacy and confidentiality) .. (integrity) ..

()

()

()

() (identification)

()

()

(social discrimination)

()

.. ..

()

(authorized person)

()

()

..

. (Vulnerable Group)

.. ..

.. ..

..

..

..

..

..

..

.

(beneficence) ( risk/benefit ratio) ( risk) (benefit)

(harm)

.

. ..

.. .. ..

.. ..

. .. (risk or harm) .. .. .. ..

(minimal risk) (slight minor increase)

.. (distributive justice) (burden) (benefit)

( fairness) ( )

. ..

..

.. ()

.. ()

..

..

.. (participant)

..

..

.. ( case record form)

.. (standard operating procedures)

. ..

()

( )

()

()

() ( )

..

..

.

..

..

. ..

.. ()

.. ( conflict of interest)

..

() / ()

() () / /

.. (minimal risk) (amendment)

..

.. /

..

. ..

( )

. ..

..

. ..

..

..

..

..

.

..

..

..

. ..

..

. (Clinical Trial)

() ()

() () (local made) (efficacy)

(double blind)

post-marketing surveillance study

..

()

() .

. . . . () () (terminate) (withdrawal)

..

..

..

() (retractors)

() / ()

() (placebo)

(sham surgery) (observational study) randomized controlled trial (minimal risk non-significant risk) (significant risk)

/

()

(electrical pacemaker) (beneficence) ( ) (fail)

..

.. (placebo)

() ()

()

() placebo effect () (minor condition) (irreversible harm) ()

..

() () (stopping rule)

, (interim

analysis) ()

. (Epidemiological Research)

. (identifiable data) , , (identifier)

. , (potentially identifiable, coded, reidentifiable)

. ,, , (de-identified, not re-identifiable, anonymous data)

..

() / ... /

()

..

() ()

minimal risk () (public benefit) () ..

.. .. ..

.. .. .. .. ..

. (Social Science Research) .. ..

.. .. .. .. .. ..

.. ..

. (Vaccine Trials) (phase of trial) .. (biological effect) (immunogenicity) (dose) (route of administration) (low risk) .. .. ( ) (live-attenuated microorganism)

(recombinant DNA)

. (Use of Human Tissue Samples)

()

() (

) ()

.. (Prospective Studies)

()

()

()

() () ()

()

() (material transfer agreement)

... (Retrospective Studies) () () () ()

. ( ) . ()

. . / / . . minimal risk . . . () (Material Transfer Agreement) . (Human Genetic Research)

(interaction) -

(social stigmata) 0

.. , (Biological Relative) () (information) (consent)

() ( )

() (linkage study)

.. () (third party)

()

.. (Genetic Counseling)

.. (Gene Alteration) (Gene Therapy)

.. (Eugenic Concern)

(mental support)

.. (Banking of Genetic Material)

()

()

.. (Commercial Use of Genetic

Data)

. (Human Gametes), (Embryo, Embryonic Stem Cell) (Fetus)

(reproductive health) (human gametes) (embryo) (fetus) (respect for the embryo and fetus)

.. (Human Gametes) ()

()

.. (Human Embryo) (Embryonic Stem Cell)

(1)

(2)

() (human cloning)

.. ..

(stem cell) ( ) ..

..

.

.

.

.

.

.

( ) ..

() ()

..

( ) ..

..

() ()

(unrelated donor)

()

()

() ()

() . ()

. () / () () . : . () () () () (Donor Registration) National Stem Cell Donor Program

()

()

()

..

/ ( )

/

() ..

/

/ / /

/ (Human Cloning)

/

()

() ()

() () () ()

() () ()

() (Pre-implantation Genetic Diagnosis)

() () () ()

( )

.

. Good Clinical Practice (GCP)

.

.

.

. (Contract Research Organization; CRO)

. CRO CRO

. CRO . CRO

. CRO

CRO

.

* ICH-Good Clinical Practice Guideline 5 2543

. . (

)

. (Clinical Trial Protocol and Protocol Amendment) ICH

.

.

.

. (remote electronic trial data systems)

.

. .

(data trail) (edit trail)

. . . .

. (transformed)

.

.

.

. ( )

.

.

. ICH

.

.

.

. /

. . GCP

. . .

.

. .

() (malpractice) (negligence)

.

.

.

.

.

. . . GCP .

.

. /

.

. (route)

.

.

. (Characterized) ( ) ()

. ()

.

.

.

( )

.

. .

( )

.

. . .

. (

)

.

.

. (specifications) ( )

.

.

.

.

. .

.

.

. . (safety updates)

. .

. . .

GCP .

.

.

. GCP

.

(extensive written guidance) GCP

.

. .

.

. ()

.

.

.

.

.

. (subject recruitment rate) .

.

(applications and submissions)

. (drop out)

.

( )

. GCP

. .

GCP

.

.

.

. (summary) / .

.

.

. .

.

. .

.

. .

GCP

.

.

. GCP

.

.

.

.

.

.

.

.

.

. .

. () .

. (

) .

. (

) () ( )

. /

.

. .

. () . (dosage regimen)

. GCP . .

* ICH-Good Clinical Practice Guideline 6 2543

.

. (scientific integrity)

. ()

. / (placebo-controlled) (parallel design)

. . .

. (dosage form)

. ()

. (stopping rules) (discontinuation criteria)

. - ()

. (trial treatment randomization codes)

. ( )

.

. .

. ( ) .

. . .

. .

. () /

.

. . (efficacy parameters) .

.

. (safety parameter) . .

.

.

. (planned interim analysis)

. () (power)

.

. . . (

/ )

. ( )

.

. . . . . . ()

- (cochlear) , (collagen) , , , , (internal stents) ,

- - (cardiopulmonary resuscitation),

cardiopulmonary bypass - - - - (absorbable hemostatic agents)

(infusion pumps)

- (contact lens) - , - (laparoscope) (hysteroscope) - (burns) - - (nerve stimulator)

(Material Transfer Agreement; MTA)

MTA . . ......[] ( ....[].) . ......[]....................................................( )

. / / ....[].

. : (material) (original material) (progeny) (unmodified descendant) (organism from organism) (unmodified derivative) (unmodified functional sub-unit) / ....[]. (vector) (modification) ( ) , , ,

. . . . . ,

. . ....[].

[ ] [ ] / / [ ] [ ] [ ] ,

. (//................................................. ............................................................. /....................................................)

. / ....[].

. ....[]."

....[].

.

. ....[].

. ....[].

. ....[]. ....[]. ....[].

. ....[].

. .. ( ) .. ....[]. ....[].

....[]. ....[].

.

. ....[].

. ....[]. ....[].

(....... )

. ....[].

....[]. ..................................................................... .................................................... (.......................................................................) (.) ..................................... .......................... ........................................... .................................................... ...................................................... ................................................................... (.........................................................) (........................................................) ..................................... ................................. ........................................... ....................................................

MTA

....[] [].

: .................................................. ....................

[ ] (......../) ......................................... [ ]

....[] ...................................................................... () .................................................... / ..................................................... /..................................................................... ............................................................................

// ...................................................................... () .................................................... / ..................................................... ........................................................................... ............................................................................

[] / . . . [] / [] /

.. -

. . . . . . . .. . . . . . .

..-

. . . . . .. . . . . .

..- . . . . . . . . . . . . . . . . . .

. ()

. , .

. . : , , .

. .. .

- ..

Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada, Tri-council Policy Statement: Ethical Conduct for Research Involving Humans. 1998 (with 2000, 2002, 2005 amendments).

Code of Federal Regulations Title 45 Part 46-Protection of Human Subjects (45 CFR 46) Revised June 18, 1991 (Effective August 19,1991) Edition October 1, 1993.

Council for International Organizations of Medical Sciences ( CIOMS). International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2001.

Council for International Organizations of Medical Sciences (CIOMS). International Guidelines for Ethical Review of Epidemiological Studies. 1991.

Dwip Kittaporn. Ethical Issues in Social Science Research. - .

European Epidemiology Group. Good Scientific Practice: Proper Conduct of Epidemiological Research.

ICH-Good Clinical Practice Guideline , .

ICH. Harmonized Guideline for Good Clinical Practice. London: EMEA, 1998.

National Health and Medical Research Council, Australia. National Statement on Ethical Conduct in Research Involving Human. 1999.

Office for Human Research Protections (OHRP). Institutional Review Board Guidebook, 1993.

. . . . .

. . . .

. . . .

. . . .

. . . . . . . . .

. (Clinical Trial). . . . . . (Human Gametes), (Embryo, Embryonic Stem Cell) (Fetus) 2545 2545 2545-2547 2547-2550 ..-